in cooperation with the Southwest Oncology Group has begun one of the largest prostate cancer prevention studies to date, the Selenium and Vitamin E Chemoprevention Trial (SELECT). The purpose of this article is to review the evidence and discuss the individual antioxidant compounds under study. The authors comprehensively reviewed the peer-reviewed literature on the chemoprevention of prostate cancer with emphasis on the antioxidants vitamin E and selenium. The credible leads for the primary prevention of prostate cancer using selenium and vitamin E have emerged as secondary findings from randomized controlled trials with corroborative evidence from observational and in vitro studies. Selenium and vitamin E are widely available compounds that are safe if taken in moderation, with relatively few adverse effects. The evidence in support of the antioxidants in the primary prevention of prostate cancer is promising, and the next step in definitively answering the question has been addressed by the investigators of SELECT. The SELECT study will define the role of the antioxidants selenium and vitamin E in the prevention of prostate cancer; complete data from the study will be available in 12 years.
Prostate cancer is the most common cancer of US men and is the second leading cause of cancer-related mortality in the US population. The incidence of prostate cancer has been increasing in most regions of the world, and worldwide has been estimated to reach 500,000 cases annually by 2000. In the United States, that figure is estimated to be 189,000 for the year 2002. 1 In contrast, the mortality rate has remained constant in generations born since the early 1900s. 2 This fact is hard to accept in light of advances in surgical, medical, radiation, and preventive management of prostate cancer. This may be the explanation for why many "traditional" urologic patients are turning to alternative modalities for treatment of their prostate cancer. Nam et al 3 were the first to report the use of complementary alternative medicine (CAM) in 27% to 39% of urology patients surveyed, of whom 24% had not informed their physicians. In the general population, estimates for the use of CAM are as high as 62%. 4 The health benefits of antioxidants were first reported and widely applied in the prevention of cardiovascular diseases, and more recently applied in prevention of cancer formation and induction of apoptosis.
Two well-accepted risk factors for prostate cancer are race and family history. However, there is a growing body of evidence that supports oxidative damage by reactive oxygen species or cellular oxidants as a cause for prostate cancer. 5 Epidemiological data suggest that environment is a major influence on prostate cancer, and this has been further linked to oxidative damage of DNA, proteins, and lipids. This has been confirmed by the association of dietary fat consumption, oxidative biomarker studies, and defects in the glutathione-s-transferase pi pathway, as well as the finding that androgens promote generation of reactive oxygen species. 6, 7 Epidemiological, preclinical, and case control studies have suggested that a diet low in saturated and animal fat may reduce the risk of cancer. The mechanism behind this decrease has not been delineated; however, several theories include the reduction of androgen levels, reduced oxidative stress, simple caloric restriction, or reduction of prostaglandins. 8 The mechanistic hypothesis for the action of antioxidants is the prevention of free radical formation and hence oxidative DNA damage. Studies have also reported apoptosis-inducing effects. Several investigators have reported that vitamin E induces G1 cell cycle arrest and apoptosis in breast, lung, and colon cancer cell lines. 9, 10 As a result of these findings, the National Cancer Institute in conjunction with the Southwest Oncology Group started (July 2001) one of the largest primary prostate cancer prevention studies to date. Investigators plan to enroll 32,400 men in the United States, Canada, and Puerto Rico over 5 years with a minimum of 7 years follow-up. Men will receive either vitamin E alone, selenium alone, vitamin E and selenium, or placebo. The purpose of this article is to review some of the studies and findings that led to the rationale for chemoprevention of prostate cancer with antioxidants and to describe the design of the Selenium and Vitamin E Chemoprevention Trial (SELECT).
Rationale Behind Chemoprevention in Prostate Cancer
The rationale for chemoprevention of prostate cancer developed as a result of the early work of Huggins and colleagues. 11 Huggins was the first to recognize, in 1941, the utility of castration and the subsequent beneficial effects on prostate cancer. This provided the groundwork for the development of hormonal ablation in prostate and breast cancer treatment, and later translated to the use of luteinizing hormone-releasing hormone analogs and finasteride in prostate cancer chemoprevention.
The evidence supporting the idea that prostate cancer can be prevented is based on epidemiological observations: (1) the incidence and mortality of prostate cancer varies according to geography, with the highest risks in the Western world and the lowest in rural Asia; (2) migrants from low-risk regions to highrisk regions always adopt the higher risk; (3) case control studies implicate dietary factors as modulators of prostate cancer risk when comparing low-and highrisk areas; (4) autopsy studies of deaths unrelated to cancer found the long latency of life-threatening prostate cancer. 12 Chemoprevention is the use of a drug, biologic or nutrient, to prevent induction, delay progression, or inhibit cancer development. 6 Some of the important requirements for an effective chemoprevention agent include experimental or epidemiologic evidence of efficacy, wide margin of safety, and a mechanistic rationale that is consistent with science. Prostate cancer is an excellent target for chemoprevention studies because of its long latency and high prevalence.
Promising Agents in the Prevention of Prostate Cancer
The Prostate Cancer Prevention Workshop, "Strategies for Developing New Clinical Trials for Prostate Cancer Chemoprevention," identified 10 important considerations for chemoprevention criteria. 12 The criteria identified apply directly to drugs; however, dietary and nutritional supplements should meet the criteria as well ( Table 1) .
There are currently a myriad of compounds under investigation in the chemoprevention of prostate cancer that cover a wide category of mechanisms: altered sex steroid signaling, differentiation and antiproliferation promoters, altered growth-signaling pathways, changes in arachidonic acid-associated signaling, gene therapy, angiogenesis inhibitors, inhibition of growth factors, and antioxidants ( Table 2) .
Recent epidemiological studies have identified a number of nutritional products including selenium, soy isoflavones, and lycopenes in the prevention of prostate cancer. Lu and colleagues 13 reported promising effects of lycopenes in prostate cancer in 2001. They examined the plasma levels of lycopene and other carotenoids and the risk of prostate cancer. They found a significant inverse relationship between plasma levels of lycopene, lutein, and zeaxanthin with respect to prostate cancer. More recently, Giovannucci and colleagues 14 confirmed the beneficial effects of lycopene on prostate cancer from the Health Professionals Follow-Up Study data. 14 
Why Selenium and Vitamin E?
Antioxidants are attractive agents for chemoprevention because of their safety profile and wide availability. Because they are readily found in the diet, the study of these agents presents a different challenge for prostate cancer prevention.
Two of the most commonly cited antioxidants in prostate cancer have been selenium and vitamin E. The credible leads for the primary prevention of prostate cancer with these agents emerged as secondary findings from randomized, controlled trials with further corroborative evidence from observational studies. The 2 landmark primary prevention studies reported in 1996 and 1998 examined selenium for skin cancer and vitamin E for lung cancer, respectively.
The first study to implicate selenium, conducted by Clark et al, 15 examined 1312 persons with a history of nonmelanoma skin cancer randomized to receive selenium (200 µg/day) or placebo and followed for 4.5 years. Although the primary endpoints of the study did not yield an effect on skin cancer, subgroup analysis revealed a two-thirds reduction in the incidence of prostate cancer in the selenium-supplemented group when compared to placebo (35 vs 13 cases, respectively). Moreover, the selenium group had a lower incidence of localized and advanced disease. The criticisms of the study include (1) effect found only on secondary endpoints and (2) only individuals from selenium-deficient areas and low to middle baseline levels showed benefit.
The second study, implicating vitamin E, was the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study, a randomized trial conducted among more than 29,000 male smokers in Finland examining the prevention of lung neoplasms. 16 All patients were heavy smokers (>20 cigarettes/day), randomized to 50 mg synthetic vitamin E, 20 mg betacarotene (β-carotene) or nothing. They reported no impact on interval between diagnosis and death. More important, secondary observations found a 32% reduced incidence of prostate cancer in the alphatocopherol (α-tocopherol) group and a 41% decrease in mortality from prostate cancer. An interesting finding is that men in the highest weight category had a 39% increased risk of developing prostate cancer.
A Closer Look at the Antioxidants Vitamin E and Selenium
Vitamin E Vitamin E is a collective term for the family of tocopherols and tocotrienols, which include the naturally occurring forms, α-, β-, and γ-tocopherol. Tocopherol is derived from the Greek words tokos (childbirth), phero (to bring forth), and ol (alcohol) and relates to the role of vitamin E in animal reproduction.
The major form of vitamin E found in human tissue is α-tocopherol, and it accordingly is the most important in nutrition and assessing dietary needs. [17] [18] [19] The tocopherols as a class are essential lipid-soluble compounds. The antioxidant properties are attributed to the inhibition of lipid peroxidation and free-radical formation. The well-established mechanism of vitamin E in free radical formation is presented in Figure 1 ; it prevents uncontrolled lipid peroxidation of membranes and breaks the free-radical cascade.
Some natural sources of vitamin E include vegetable oils, eggs, milk, tomatoes, nuts, and rice bran. Table 3 provides a list of natural sources and their respective vitamin E content.
The recommended daily allowance, as part of the dietary reference intake, for vitamin E is 15 mg/day (1 mg = 1.5 IU) of the most biologically active and useable form, α-tocopherol. 20 Vitamin E is readily excreted in urine and feces, and absorption is heavily dependent on fat intake. Research to date has shown beneficial health effects in the dose range of 200 to 400 IU/day. Meydani et al 21 found that 200 IU was optimal for improving immune response in the elderly, and Jialal et al 22 determined that 400 IU is the minimum for reducing susceptibility of low-density lipoproteins to oxidation.
The deficiency of vitamin E is a rare occurrence in the Western world, but when it does occur, some common effects include a shortened red blood cell life span (< 5 mg/L serum vitamin E), with an increased risk for hemolysis, and disruption in myelination leading to neurological manifestations (motor function and vision). In patients with fat malabsorption conditions, the deficiency of this lipidsoluble vitamin may be seen. High doses of vitamin E have proven to be nontoxic, and daily doses >450 IU are considered harmless. 17 The tolerable upper intake levels, or the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects to almost all individuals in the general population, for vitamin E is 1000 mg/day (1500 IU). 20 The only reported toxicity secondary to high dosing includes excessive bleeding in the setting of surgery or anticoagulation. 18, 19 Some of the more common reasons people take vitamin E supplementation include the following: enhanced immune response, reduced risk of cancer, and reduced risk of cardiovascular atherosclerotic disease. The effects of vitamin E intake and serum concentrations on lung cancer have been extensively studied, and the results have been equivocal. 23 Some authors believe the doses used were too low. However, because of the secondary findings reported in the ATBC Finnish study, vitamin E looks promising in prostate cancer.
In vitro studies of α-tocopherol effects on various prostate cancer lines have supported the hypothesis of apoptosis induction. A study conducted by Gunawardena et al 7 diagnosed aggressive prostate cancer and found that smokers with the highest levels of serum αtocopherol experienced a 50% decrease in the risk of aggressive prostate cancer, whereas no association was found for nonsmokers. More recently, the US Health Professional Follow-Up Study reported on 1896 total cases of prostate cancer and found no association of vitamin E in nonsmokers. 26 However, among current and recent smokers, users of >100 IU/day of vitamin E had a 56% decreased risk of advanced or fatal prostate cancer compared to nonusers.
Selenium
Selenium is an essential nonmetallic trace element that cannot be manufactured by the human body. It is named after Selene, the goddess of the moon. Selenium is essential for the activity of glutathione peroxidase, an enzyme that protects against reactive oxygen species and subsequent cell membrane damage. Based on this mechanism, it has been reported that selenium balances the deficiency of vitamin E. 18 Figure 2 describes the antioxidant effects of selenium in relation to the steps of lipid peroxidation. The dietary intake of selenium in the United States varies geographically based on soil content; however, the national food distribution system partly negates this difference. Interestingly, the Japanese have the lowest incidence of prostate cancer and their average selenium consumption is around 130 µg/day. 27 Some consistently good natural sources for selenium include tuna, kidney, liver, seafood, Brazil nuts, broccoli, tomatoes, onions, orange juice, whole wheat, bran, and wheat germ. The recommended daily allowance for selenium is 55 µg/day for men and women. 20 Selected dietary sources for selenium and their content are listed in Table 4 .
Vitamin E and Selenium in Prostate Cancer Prevention
Selenium is readily absorbed and distributed throughout the body except in fat. The primary route of excretion is in urine. The deficiency of selenium, although rare, has been reported in areas with low selenium soil content to graze animals and grow plants, such as southern regions of China. The most serious condition secondary to selenium deficiency is Keshan disease, named after the province of China, described as dilated cardiomyopathy, predominantly in children, secondary to decreased selenium intake (< 19 µg/day). Recent evidence suggests a virus as the cause and the deficiency of selenium a predisposing factor. 28, 29 Selenium deficiency can also be seen in patients on chronic total parenteral nutrition administration. These patients report muscle weakness and discomfort as the main complaint in light of selenium deficiency.
Studies on the toxicities of selenium have revealed adverse effects in extremes of consumption, >3000 µg/day, well above the average intake of 80 µg/day. 29 Toxic effects of selenium secondary to excessive consumption include nausea, weakness, diarrhea, hair loss, nail changes, skin lesions, and mottling of teeth. Although none of the side effects are life threatening, they are nonetheless unpleasant and patients should be warned before administering these compounds.
Commonly cited benefits of selenium include the inhibition of tumorigenesis. The earliest evidence for the role of selenium in prostate cancer emerged as early as 1983, and further evidence was reported in 1990. 30 However, in these early studies the number of cases was too low or no association was found. The evidence that most investigators refer to is the study conducted by Clark et al. 15 One of the most important observational studies, the Health Professional Follow-Up Study conducted by Yoshizawa et al, 31 examined selenium levels in toenails of 33,000 men and the incidence of prostate cancer. The investigators reported a 50% to 66% reduction in advanced prostate cancer with high selenium levels in toenails. The estimated daily intake among the study participants was 159 µg/day.
Two additional controlled studies conducted in China identified a reduced incidence of cancer in groups using antioxidants and vitamins. They did not examine prostate cancer specifically but, rather, reported effects on stomach and esophageal cancers. Blot and colleagues 32 enrolled 29,000 people in Linxian, China, to study the effects of vitamin E (30 IU), β-carotene (15 mg), and selenium (50 µg) supplementation. They reported a 13% lower risk of deaths from all cancers and a 21% lower risk of death from stomach cancer between the antioxidant and untreated groups. Li and colleagues 33 enrolled 3000 subjects with esophageal dysplasia and placed them on either 26 vitamins and minerals (including vitamin E and selenium) or nothing. They reported a 7% reduced mortality for all cancers and 14% for stomach cancer. Again, they did not examine prostate cancer specifically.
SELECT Study Design
The National Cancer Institute and Southwest Oncology Group will enroll a total of 32,400 patients, without evidence of prostate cancer, from more than 400 participating study sites in the United States, Puerto Rico, and Canada. The investigators hope to enroll patients in the first 5 years, with a minimum of 7-year follow-up.
The study is designed as a prospective, doubleblind, placebo-controlled multicenter trial with a 2 × 2 factorial design. Therefore, patients will either receive selenium or vitamin E alone, both in combination, or placebo ( Figure 3 ). The dosing for selenium and vitamin E will be 200 µg and 400 IU, respectively. The primary endpoints investigators have determined for the study will be the diagnosis of histologic cancer or the diagnosis of clinically evident prostate cancer with an elevated TPSA > 50 ng/mL and positive bone scan study. Investigators hope to further define the various effects of antioxidants on other diseases and have determined secondary objectives to fulfill the lack of supportive evidence: prostate cancer-free survival; incidence and survival of lung, colon, and all cancers combined; overall survival; and serious cardiovascular events. With access to a large resource and database, they hope to further define the epidemiology, molecular biomarkers, dietary nutrition assessment, and impact on quality of life.
Conclusions
Are the antioxidants selenium and vitamin E ready for trials in the prevention of prostate cancer together or alone? It is known that in combination, selenium and vitamin E compensate for the deficiency of each other and act synergistically against reactive oxygen species formation. Moreover, the converging evidence from epidemiologic, animal, and molecular biology studies strongly supports the role of vitamin E and selenium in the prevention of prostate cancer. All this evidence has caught the attention not only of the National Cancer Institute but of researchers worldwide-the Australian Prostate Cancer Prevention Trial Using Selenium trial is an example of an ongoing study to define the role of selenium in familial prostate cancer. 34 The early experience with the education and enrollment of patients in our institution has proved challenging. Many men who are interested simply do not qualify due to the inclusion/exclusion criteria. Others refuse to participate secondary to a risk of not receiving the beneficial antioxidants. A recent study conducted by Lee et al 35 addressed the issue of interest among patients in participating in prostate cancer chemoprevention trials. The study reported that minorities were more likely to participate when compared to whites (70% vs 30%). Moreover, married men were more willing than singles to participate.
Other challenges of the study will be to ensure 100% compliance during the study period and the avoidance of surreptitious supplement use because of the easy access to the study agents. There is also a concern over the increasing use of saw palmetto for benign prostatic hyperplasia, since its use is a criterion of exclusion for participation in SELECT. 36 The role of physicians, especially urologists, will be to reinforce the positive benefits for future generations of men. Conclusions drawn from the SELECT data will truly benefit the sons and grandsons of the participants. Moreover, physicians have the responsibility to educate and inform patients that although these compounds are readily available, they can have serious adverse events if not taken properly.
Investigators will undoubtedly be busy enrolling patients over the next 5 years, and follow-up over a minimum of 7 years will be needed before we obtain the earliest results of the study. Secondary to the long latency of prostate cancer, a minimum of 7 years and a maximum of 12 years of follow-up will be reported from this study. Obviously, with all the touted benefits of the antioxidants in the treatment of cardiovascular disease and cancer, the SELECT data will provide hard scientific evidence for or against vitamin E and selenium.
Meanwhile, the National Cancer Institute is constantly scrutinizing various promising compounds for cancer treatment and prevention. Other potential chemopreventive agents include lycopenes, thioallyl components of garlic, sulphoraphane (cruciferous vegetables), green tea polyphenols, and soy. Studies examining these other agents will need to focus on intermediate endpoint biomarkers and will be on a scale much smaller than SELECT due to the nature of the study designs. 
